Department of Nephrology, Taizhou First People's Hospital, Taizhou 225300, China.
Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine Nanjing 210029, China.
Acta Pharmacol Sin. 2018 Feb;39(2):222-229. doi: 10.1038/aps.2017.87. Epub 2017 Aug 31.
Glomerular sclerosis is characterized by mesangial cell proliferation and progressive extracellular matrix (ECM) accumulation. CCN3 belongs to the CCN family of matrix proteins; increasing evidence suggests that CCN3 is an endogenous negative regulator of the ECM and fibrosis. However, the exact role of CCN3 in the accumulation of ECM remains unknown. The aim of the present study was to investigate the effects of CCN3 on TGF-β1-induced production of ECM in human mesangial cells (HMCs) in vitro. Treatment with TGF-β1 (0.5-2.0 ng/mL) suppressed the mRNA and protein expression of CCN3 in HMCs in dose- and time-dependent manners. Furthermore, treatment with TGF-β1 significantly increased the expression of the two markers of renal fibrosis, fibronectin (FN) and type I collagen (COLI), in HMCs. Moreover, treatment with TGF-β1 significantly decreased the expression of metalloproteinase (MMP)-2 and MMP-9, and markedly increased the expression of tissue inhibitor of metalloproteinase (TIMP)-1 in HMCs. Pretreatment of HMCs with exogenous CCN3 (5-500 ng/mL) or overexpression of CCN3 significantly attenuated TGF-β1-induced changes in FN, COLI, MMP-2, MMP-9 and TIMP-1 in HMCs. These results suggest that CCN3 suppresses TGF-β1-induced accumulation of ECM in HMCs. CCN3 may have potential as a novel therapeutic target for alleviating glomerulosclerosis.
肾小球硬化症的特征是系膜细胞增殖和进行性细胞外基质(ECM)积聚。CCN3 属于细胞外基质蛋白的 CCN 家族;越来越多的证据表明,CCN3 是 ECM 和纤维化的内源性负调节剂。然而,CCN3 在 ECM 积聚中的确切作用尚不清楚。本研究旨在探讨 CCN3 对 TGF-β1 诱导的人肾小球系膜细胞(HMC)中 ECM 产生的影响。TGF-β1(0.5-2.0ng/mL)处理以剂量和时间依赖的方式抑制 HMC 中 CCN3 的 mRNA 和蛋白表达。此外,TGF-β1 处理显著增加了 HMC 中两种肾纤维化标志物纤连蛋白(FN)和 I 型胶原(COLI)的表达。此外,TGF-β1 处理显著降低了 MMP-2 和 MMP-9 的表达,并显著增加了 HMC 中金属蛋白酶抑制剂(TIMP)-1 的表达。外源性 CCN3(5-500ng/mL)预处理或 CCN3 过表达显著减弱了 TGF-β1 诱导的 HMC 中 FN、COLI、MMP-2、MMP-9 和 TIMP-1 的变化。这些结果表明 CCN3 抑制 TGF-β1 诱导的 HMC 中 ECM 的积聚。CCN3 可能有潜力成为缓解肾小球硬化症的新的治疗靶点。